Richard D. Pilnik is Director at DiaMedica Therapeutics Inc. (DMAC). They have made 7 open-market trades across 1 company since 2018, most recently 2025-04-07.
CIK 0001760016
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $550K since 2018, never a sale. Across 7 scored buys the stock is up 13.7% at ninety days, and 10.0 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| DMAC | 312,995 | $2.4M |
Shares reported on the most recent Form 4, priced at the 2025-04-08 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 71% | 71% | 71% |
| Avg Move | +3.5% | +22.3% | +13.7% |
| Alpha | +4.1% | +20.9% | +10.0% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DMAC | BUY | 2023-06-23 | 2023-06-26 | $3.91 | $300K | -11.1% | -25.1% | -42.1% |
| DMAC | BUY | 2022-12-05 | 2022-12-05 | $1.39 | $49K | +12.7% | +8.2% | +32.8% |
| DMAC | BUY | 2021-08-16 | 2021-08-17 | $3.27 | $49K | +7.2% | +8.3% | +7.8% |
| DMAC | BUY | 2020-12-04 | 2020-12-04 | $5.37 | $54K | +20.7% | +74.6% | +50.4% |
| DMAC | BUY | 2019-08-16 | 2019-08-19 | $2.56 | $20K | +15.2% | +10.0% | +50.0% |
| DMAC | BUY | 2019-05-31 | 2019-05-31 | $2.80 | $53K | +6.2% | +82.8% | +8.3% |
| DMAC | BUY | 2018-12-11 | 2018-12-11 | $4.00 | $25K | -26.7% | -2.7% | -11.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.